X
[{"orgOrder":0,"company":"Avance Clinical","sponsor":"Atossa Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Odyssey Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Avance Clinical
Filters
Companies By Therapeutic Area
Details:
Under the agreement, Avance Clinical will manage the Phase 1 clinical trial of EB-373 in coordination with Enveric. EB-373 is designed as a next-generation proprietary psilocin prodrug and developed leveraging its Psybrary™ drug discovery platform to target anxiety disorders.
Lead Product(s):
EB-373
Therapeutic Area: Psychiatry/Psychology
Product Name: EB-373
Highest Development Status: Preclinical
Product Type: Small molecule
Recipient:
Enveric Biosciences
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
March 23, 2023
Details:
No severe adverse events were noted as PRV-002 was well-tolerated for all cohorts. No delays were instituted between cohorts. Vital signs, EKG readings, sleep patterns and breathing function were all normal through the entirety of the study.
Lead Product(s):
PRV-002
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: PRV-002
Highest Development Status: Phase I
Product Type: Small molecule
Recipient:
Odyssey Health
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 28, 2022
Details:
The study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups.
Lead Product(s):
AT-301
Therapeutic Area: Infections and Infectious Diseases
Product Name: AT-301
Highest Development Status: Preclinical
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Atossa Therapeutics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
July 22, 2020